Definium Therapeutics, Inc. reports a Return on Equity (ROE) of -85.19%.

What is DFTX's dividend yield?

Definium Therapeutics, Inc. offers a dividend yield of 0.00%.

What is DFTX's Quality Score?

Our AI rates DFTX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy DFTX?

Our AI Timing Score for DFTX is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does DFTX belong to?

Definium Therapeutics, Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Definium Therapeutics, Inc. (DFTX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

DFTX AI Analysis Summary

Our AI summary for DFTX: Definium Therapeutics, Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -85.19%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

DFTX

Definium Therapeutics, Inc.

US:NASDAQ STOCK Healthcare >> Biotechnology News 90

USD 41.79

-1.73 (-3.98%) Day Change

Watchlist Portfolio Compare Chart

0.15

D/E

-85.2%

ROE

-59.2%

ROA

0.00%

Div Yield

DEFINIUM THERAPEUTICS, INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 41.79 Price -1.73 (-3.98%) Day Change	NEWS SCORE: 90

DFTX, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	90
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	41.79
PBV / Sector	20.72 / 44,219.29
Earning Per Share	-1.72

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	82.03 M
Average 1W Daily Value	79.88 M

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.22
NPM Average (%) / Sector	N/A / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-59.19 / 185,260.96
ROA Average (%) / Sector	-49.44 / 36,684.70
ROA Change Average (%) / Sector	33.68 / 422,221.66 GREAT
ROE (%) / Sector	-85.19 / 243,762.23
ROE Average (%) / Sector	-69.13 / 48,758.47
ROE Change Average (%) / Sector	59.80 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:24
Symbol	DFTX
Name	DEFINIUM THERAPEUTICS, INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	132.74 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	5,776.99 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: One World Trade Center, New York, NY, United States, 10007

Phone: 212 220 6633

Website: https://definiumtx.com

Employees: 105

Sector: Healthcare >> Biotechnology

Description: Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.